NJ-OPEX-CORPORATION
28.3.2022 12:02:12 CEST | Business Wire | Press release
OPEX® Corporation , a global leader in warehouse automation technology, has added an innovative, industry-leading goods-to-person (G2P) solution to its Warehouse Automation portfolio.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220328005036/en/
The Infinity™ solution combines unparalleled storage density, configurability, and flexibility to meet the most pressing warehouse automation challenges for companies handling micro-fulfillment , omni-channel distribution, store replenishment, and ecommerce .
“Our focus is on engineering exciting new solutions that address unmet and evolving customer needs,” said Alex Stevens, President, OPEX Warehouse Automation. “The Infinity solution represents the next generation of goods-to-person technology to perfectly complement our existing Warehouse Automation product line.”
Automated G2P technology delivers the right item or SKU at the right time to the right operator or workstation, increasing productivity, throughput, and labor utilization by eliminating wasted time.
Powered by OPEX’s proprietary Cortex™ software platform , the Infinity G2P solution is engineered for maximum flexibility and scalability in both throughput and storage. Key benefits include reducing labor while increasing efficiency, storage density, and configurability.
Wireless Infinity iBOT® robotic vehicles access all inventory and port stations, moving freely underneath and throughout the system with no wasted mechanical motion, saving time and costs. Infinity iBOT robots are easily scalable by adding more iBOTs, presentation ports, and grids.
Unlike other competitive systems, the Infinity solution offers up to 35 percent more storage capacity with bot paths that are up to 65 percent more efficient.
The Infinity goods-to-person system utilizes a unique interlocking system to store totes triple-deep, eliminating wasted space and maximizing storage density. A configurable rack design optimizes warehouse space despite obstructions that may exist, such as columns or other equipment. The Infinity system’s flexibility also accommodates varied workflows and layouts.
The innovative Infinity solution was unveiled today at MODEX 2022 , the industry’s premier material handling expo that showcases the latest in manufacturing and supply chain technology.
“Ecommerce is growing exponentially,” said Stevens. “Companies today need dependable yet advanced technology, the resiliency to meet shifting and seasonal demands, fast and accurate fulfillment, the ability to maximize space, and a partner they can trust. OPEX and the Infinity solution deliver all of this and more.”
Founded in 1973, OPEX brings generations of industry expertise and a proven track record developing first-class automation capabilities. The company is vertically integrated—innovating, engineering, manufacturing, selling, and servicing all of its automated solutions. This translates to the highest degree of quality equipment, reliable operations, product longevity, and an exceptional client experience.
The Infinity solution joins the existing Warehouse Automation portfolio at OPEX, which includes Sure Sort® —the industry-leading, high-speed, small-item robotic sorting system; and Perfect Pick® , a robotic goods-to-person picking solution that dramatically improves speed, efficiency, and reliability. All three solutions are custom configured for each client and designed to completely transform supply chain infrastructure.
To learn more, please visit warehouseautomation.com .
About OPEX
OPEX Corporation is a global leader in Next Generation Automation, providing innovative, unique solutions for warehouse, document and mail automation. With headquarters in Moorestown, NJ, USA—and facilities in Pennsauken, NJ; Plano, TX; France; Germany; Switzerland; the United Kingdom; and Australia—OPEX has more than 1,500 employees who are continuously reimagining and delivering customized, scalable technology solutions that solve the business challenges of today and the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220328005036/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom